Vasarya Therapeutics, Inc.

Camden, DE

UEI
PFB5FMPM2666
CAGE
9EY84
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
2140 S Dupont Hwy, Camden, DE 19934, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Vasarya Therapeutics, Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Translating a novel therapeutic approach to the treatment for idiopathic pulmonary fibrosis - project abstract the… Grant · R44HL170936 National Heart Lung and Blood Institute $1,463,750
Targeting a disease-specific conformation of fibronectin as a novel approach for liver fibrosis treatment - project… Grant · R41DK138519 National Institute of Diabetes and Digestive and Kidney Diseases $591,842

Quick answers

What is Vasarya Therapeutics, Inc.'s UEI?

Vasarya Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is PFB5FMPM2666.

What is Vasarya Therapeutics, Inc.'s CAGE code?

Vasarya Therapeutics, Inc.'s CAGE code is 9EY84.

What is Vasarya Therapeutics, Inc.'s primary NAICS code?

Vasarya Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Vasarya Therapeutics, Inc. located?

Vasarya Therapeutics, Inc.'s physical address in SAM.gov is 2140 S Dupont Hwy, Camden, DE 19934, USA.

Is Vasarya Therapeutics, Inc. registered in SAM.gov?

Yes. Vasarya Therapeutics, Inc.'s SAM.gov registration is active through June 10, 2027.

What is Vasarya Therapeutics, Inc.'s most recent federal award?

Vasarya Therapeutics, Inc.'s most recent federal grant award is Translating a novel therapeutic approach to the treatment for idiopathic pulmonary fibrosis - project abstract the… (R44HL170936), from National Heart Lung and Blood Institute, on September 15, 2024.

On GovTribe

See Vasarya Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login